By this point we’ve all heard about the rising cost of prescription drugs; last month we ran an introduction to this series explaining just that. But what’s the real story behind the trend? Is it simply greedy CEOs hoping to rake in more profits and garner more investor speculation, or is the reality more complicated? […]
New Series Introduction: Prescription Drug Pricing
Public policy is complicated. To make it less complicated we’ve decided to break it down by creating an initiative dedicated to the rigorous study of more singular policy topics released in series. Over the coming months readers can expect a thematic stream of content from these series, that tell a story about a relevant but […]